The company and MassDevelopment have also finalized agreements related to the facility’s utility infrastructure, including waste water treatment and use of electricity, water and natural gas.
The facility is projected to be operationally complete in 2009, and the company plans to submit the site for regulatory approval in 2010.
The new Devens manufacturing facility is expected to support increased production capacity for commercially available biologic compounds, such as Orencia (abatacept), and help meet future production needs of biologic compounds currently in development, including the company’s investigational treatments for solid organ transplant rejection and certain types of cancers.